Hunt Andrea
Known title: DirectorCIK: 0001720487
Associated companies
Transaction History
| GYRE | ▼ Sell | Other | 28 | — | 8/31/2023 | View on chart |
| GYRE | ▲ Buy | Grant | 7,521 | $0 | 1/7/2022 | View on chart |
| GYRE | ▲ Buy | Grant | 1,824 | $0 | 10/1/2021 | View on chart |
| GYRE | ▼ Sell | Other | 28 | — | 8/31/2023 | View on chart |
| GYRE | ▲ Buy | Grant | 7,521 | $0 | 1/7/2022 | View on chart |
| GYRE | ▲ Buy | Grant | 1,824 | $0 | 10/1/2021 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Gyre Therapeutics Schedules Investor Meetings for September
Gyre Therapeutics has announced participation in upcoming investor conferences scheduled for September. The company will engage with institutional investors and analysts through these scheduled meetings. Shares are currently trading near established support at $6.32, within a 52-week range of $5.44 to $9.42. Three analysts currently maintain an average price target of $18.67.
Gyre Therapeutics Schedules Investor Meetings for September. Gyre Therapeutics has announced participation in upcoming investor conferences scheduled for September. The company will engage with institutional investors and analysts through these scheduled meetings. Shares are currently trading near established support at $6.32, within a 52-week range of $5.44 to $9.42. Three analysts currently maintain an average price target of $18.67.